TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

January 5, 2023

https://www.globenewswire.com/news-release/2023/01/05/2583504/0/en/TScan-Therapeutics-Announces-2023-Clinical-Plans-and-Highlights-Recent-Progress.html

Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023

Advancing solid tumor program with development of several TCRs for multiple HLAs across multiple targets; INDs filed for two MAGE-A1 TCRs (TSC-204-A0201 and TSC-204-C0702) as well as IND for multiplexing TCRs

Read more at globenewswire.com

Related news for (TCRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.